id,group_id,source,exact,prefix,suffix,anno_type,position_type,start,end,tags,all,origin_tags,comment,user,title,created
xAEqwuaAEemr1bvMJ1nowA,jgraPEon,https://europepmc.org/articles/PMC5026174/,Anxiety,n the Hamilton Rating Scale for ,) are normally distributed with ,TextQuoteSelector,TextPositionSelector,78547,78554,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis-driven selection rules.,2019-10-04T08:27:12.688320+00:00
uTocIOaAEemrdmsJ6f9IAw,jgraPEon,https://europepmc.org/articles/PMC5026174/,generalised anxiety disorder, a placebo for the treatment of ,. We assume that the outcomes (t,TextQuoteSelector,TextPositionSelector,78439,78467,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis-driven selection rules.,2019-10-04T08:26:54.740821+00:00
oCWOaOaAEemzQIdztilAIw,jgraPEon,https://europepmc.org/articles/PMC5026174/,CHN,"mance of the Kimani et al. (D
1,","), naïve (D
1,MLE) and stage 2 (",TextQuoteSelector,TextPositionSelector,58292,58295,WT_GP,no,[WT_GP],,acct:farheen.s@hypothes.is,Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis-driven selection rules.,2019-10-04T08:26:12.570061+00:00
lT0ayuaAEem_34PgKqIfxQ,jgraPEon,https://europepmc.org/articles/PMC5026174/,MLE,e maximum likelihood estimator (,") for θ
S is D
S,MLE=Z
S,MLE−Z
0",TextQuoteSelector,TextPositionSelector,20316,20319,WT_GP,yes,[WT_GP][ALL],,acct:farheen.s@hypothes.is,Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis-driven selection rules.,2019-10-04T08:25:54.327269+00:00
g0_u8OaAEem67n_ED_0A1g,jgraPEon,https://europepmc.org/articles/PMC5026174/, colorectal cancer ,on 2 and treatment selection for,3. Regulatory guidance dealing w,TextQuoteSelector,TextPositionSelector,8727,8746,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis-driven selection rules.,2019-10-04T08:25:24.203501+00:00
eGJVWuaAEemcj-dTrVvuyg,jgraPEon,https://europepmc.org/articles/PMC5026174/,acute myocardial infarction,"structive pulmonary disorder 1, ", 2 and treatment selection for c,TextQuoteSelector,TextPositionSelector,8670,8697,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis-driven selection rules.,2019-10-04T08:25:05.800687+00:00
VwX_tu_kEemDEJMQ69gWbg,jgraPEon,https://europepmc.org/articles/PMC5026174/,chronic obstructive pulmonary disorder,tice include dose selection for ," 1, acute myocardial infarction ",TextQuoteSelector,TextPositionSelector,8628,8666,WS_DS,no,WS_DS,,acct:farheen.s@hypothes.is,Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis-driven selection rules.,2019-10-16T07:12:39.998964+00:00
